false2021Q3000115603912/3125,49522,22267606532——100,000,000100,000,000————0.010.01900,000,000900,000,000242,847,676245,401,430242,847,676245,401,43034502025282543510—5——4211274100274171682171222109218171108271224.0000011560392021-01-012021-09-30xbrli:shares00011560392021-10-14iso4217:USD00011560392021-09-3000011560392020-12-31iso4217:USDxbrli:shares00011560392021-07-012021-09-3000011560392020-07-012020-09-3000011560392020-01-012020-09-3000011560392019-12-3100011560392020-09-300001156039us-gaap:CommonStockMember2020-12-310001156039us-gaap:AdditionalPaidInCapitalMember2020-12-310001156039us-gaap:RetainedEarningsMember2020-12-310001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001156039us-gaap:NoncontrollingInterestMember2020-12-310001156039us-gaap:RetainedEarningsMember2021-01-012021-03-310001156039us-gaap:NoncontrollingInterestMember2021-01-012021-03-3100011560392021-01-012021-03-310001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001156039us-gaap:CommonStockMember2021-01-012021-03-310001156039us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001156039us-gaap:CommonStockMember2021-03-310001156039us-gaap:AdditionalPaidInCapitalMember2021-03-310001156039us-gaap:RetainedEarningsMember2021-03-310001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001156039us-gaap:NoncontrollingInterestMember2021-03-3100011560392021-03-310001156039us-gaap:RetainedEarningsMember2021-04-012021-06-300001156039us-gaap:NoncontrollingInterestMember2021-04-012021-06-3000011560392021-04-012021-06-300001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001156039us-gaap:CommonStockMember2021-04-012021-06-300001156039us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001156039us-gaap:CommonStockMember2021-06-300001156039us-gaap:AdditionalPaidInCapitalMember2021-06-300001156039us-gaap:RetainedEarningsMember2021-06-300001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001156039us-gaap:NoncontrollingInterestMember2021-06-3000011560392021-06-300001156039us-gaap:RetainedEarningsMember2021-07-012021-09-300001156039us-gaap:NoncontrollingInterestMember2021-07-012021-09-300001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300001156039us-gaap:CommonStockMember2021-07-012021-09-300001156039us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001156039us-gaap:CommonStockMember2021-09-300001156039us-gaap:AdditionalPaidInCapitalMember2021-09-300001156039us-gaap:RetainedEarningsMember2021-09-300001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300001156039us-gaap:NoncontrollingInterestMember2021-09-300001156039us-gaap:CommonStockMember2019-12-310001156039us-gaap:AdditionalPaidInCapitalMember2019-12-310001156039us-gaap:RetainedEarningsMember2019-12-310001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001156039srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMemberus-gaap:AccountingStandardsUpdate201613Member2019-12-310001156039srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AccountingStandardsUpdate201613Member2019-12-310001156039srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMemberus-gaap:RetainedEarningsMember2019-12-310001156039srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember2019-12-310001156039us-gaap:RetainedEarningsMember2020-01-012020-03-3100011560392020-01-012020-03-310001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310001156039us-gaap:CommonStockMember2020-01-012020-03-310001156039us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-310001156039us-gaap:CommonStockMember2020-03-310001156039us-gaap:AdditionalPaidInCapitalMember2020-03-310001156039us-gaap:RetainedEarningsMember2020-03-310001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-3100011560392020-03-310001156039us-gaap:RetainedEarningsMember2020-04-012020-06-3000011560392020-04-012020-06-300001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-04-012020-06-300001156039us-gaap:CommonStockMember2020-04-012020-06-300001156039us-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-300001156039us-gaap:CommonStockMember2020-06-300001156039us-gaap:AdditionalPaidInCapitalMember2020-06-300001156039us-gaap:RetainedEarningsMember2020-06-300001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-3000011560392020-06-300001156039us-gaap:RetainedEarningsMember2020-07-012020-09-300001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300001156039us-gaap:CommonStockMember2020-07-012020-09-300001156039us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300001156039us-gaap:CommonStockMember2020-09-300001156039us-gaap:AdditionalPaidInCapitalMember2020-09-300001156039us-gaap:RetainedEarningsMember2020-09-300001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-30antm:medical_memberantm:countyantm:statesxbrli:pure0001156039antm:GovernmentBusinessSegmentMemberantm:MMMHoldingsMember2021-09-300001156039antm:GovernmentBusinessSegmentMemberus-gaap:FiniteLivedIntangibleAssetsMemberantm:MMMHoldingsMembersrt:MinimumMember2021-01-012021-09-300001156039srt:MaximumMemberantm:GovernmentBusinessSegmentMemberus-gaap:FiniteLivedIntangibleAssetsMemberantm:MMMHoldingsMember2021-01-012021-09-300001156039antm:OtherSegmentMemberantm:MyNEXUSMember2021-09-300001156039antm:OtherSegmentMemberantm:MyNEXUSMemberus-gaap:CustomerRelationshipsMember2021-01-012021-09-300001156039antm:OtherSegmentMemberantm:BeaconHealthOptionsMember2020-12-310001156039antm:OtherSegmentMemberantm:BeaconHealthOptionsMember2021-01-012021-09-300001156039antm:OtherSegmentMemberantm:BeaconHealthOptionsMember2021-09-300001156039antm:OtherSegmentMemberantm:BeaconHealthOptionsMemberus-gaap:CustomerRelationshipsMembersrt:MinimumMember2021-01-012021-09-300001156039antm:OtherSegmentMembersrt:MaximumMemberantm:BeaconHealthOptionsMemberus-gaap:CustomerRelationshipsMember2021-01-012021-09-30antm:individuals0001156039antm:BeaconHealthOptionsMember2020-02-280001156039antm:MyNEXUSMember2021-04-280001156039us-gaap:EmployeeSeveranceMemberantm:CommercialSpecialtyBusinessSegmentMember2020-12-310001156039us-gaap:EmployeeSeveranceMemberantm:GovernmentBusinessSegmentMember2020-12-310001156039us-gaap:EmployeeSeveranceMemberantm:IngenioRxSegmentMember2020-12-310001156039antm:OtherSegmentMemberus-gaap:EmployeeSeveranceMember2020-12-310001156039us-gaap:EmployeeSeveranceMember2020-12-310001156039us-gaap:EmployeeSeveranceMemberantm:CommercialSpecialtyBusinessSegmentMember2021-01-012021-09-300001156039us-gaap:EmployeeSeveranceMemberantm:GovernmentBusinessSegmentMember2021-01-012021-09-300001156039us-gaap:EmployeeSeveranceMemberantm:IngenioRxSegmentMember2021-01-012021-09-300001156039antm:OtherSegmentMemberus-gaap:EmployeeSeveranceMember2021-01-012021-09-300001156039us-gaap:EmployeeSeveranceMember2021-01-012021-09-300001156039us-gaap:EmployeeSeveranceMemberantm:CommercialSpecialtyBusinessSegmentMember2021-09-300001156039us-gaap:EmployeeSeveranceMemberantm:GovernmentBusinessSegmentMember2021-09-300001156039us-gaap:EmployeeSeveranceMemberantm:IngenioRxSegmentMember2021-09-300001156039antm:OtherSegmentMemberus-gaap:EmployeeSeveranceMember2021-09-300001156039us-gaap:EmployeeSeveranceMember2021-09-300001156039us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FixedMaturitiesMember2021-09-300001156039us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FixedMaturitiesMember2021-01-012021-09-300001156039us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FixedMaturitiesMember2021-09-300001156039us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FixedMaturitiesMember2021-01-012021-09-300001156039us-gaap:ForeignGovernmentDebtMemberus-gaap:FixedMaturitiesMember2021-09-300001156039us-gaap:ForeignGovernmentDebtMemberus-gaap:FixedMaturitiesMember2021-01-012021-09-300001156039us-gaap:USStatesAndPoliticalSubdivisionsMemberus-gaap:FixedMaturitiesMember2021-09-300001156039us-gaap:USStatesAndPoliticalSubdivisionsMemberus-gaap:FixedMaturitiesMember2021-01-012021-09-300001156039us-gaap:CorporateDebtSecuritiesMemberus-gaap:FixedMaturitiesMember2021-09-300001156039us-gaap:CorporateDebtSecuritiesMemberus-gaap:FixedMaturitiesMember2021-01-012021-09-300001156039us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FixedMaturitiesMember2021-09-300001156039us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FixedMaturitiesMember2021-01-012021-09-300001156039us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FixedMaturitiesMember2021-09-300001156039us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FixedMaturitiesMember2021-01-012021-09-300001156039us-gaap:FixedMaturitiesMemberus-gaap:OtherAggregatedInvestmentsMember2021-09-300001156039us-gaap:FixedMaturitiesMemberus-gaap:OtherAggregatedInvestmentsMember2021-01-012021-09-300001156039us-gaap:FixedMaturitiesMember2021-09-300001156039us-gaap:FixedMaturitiesMember2021-01-012021-09-300001156039us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FixedMaturitiesMember2020-12-310001156039us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FixedMaturitiesMember2020-01-012020-12-310001156039us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FixedMaturitiesMember2020-12-310001156039us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FixedMaturitiesMember2020-01-012020-12-310001156039us-gaap:ForeignGovernmentDebtMemberus-gaap:FixedMaturitiesMember2020-12-310001156039us-gaap:ForeignGovernmentDebtMemberus-gaap:FixedMaturitiesMember2020-01-012020-12-310001156039us-gaap:USStatesAndPoliticalSubdivisionsMemberus-gaap:FixedMaturitiesMember2020-12-310001156039us-gaap:USStatesAndPoliticalSubdivisionsMemberus-gaap:FixedMaturitiesMember2020-01-012020-12-310001156039us-gaap:CorporateDebtSecuritiesMemberus-gaap:FixedMaturitiesMember2020-12-310001156039us-gaap:CorporateDebtSecuritiesMemberus-gaap:FixedMaturitiesMember2020-01-012020-12-310001156039us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FixedMaturitiesMember2020-12-310001156039us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FixedMaturitiesMember2020-01-012020-12-310001156039us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FixedMaturitiesMember2020-12-310001156039us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FixedMaturitiesMember2020-01-012020-12-310001156039us-gaap:FixedMaturitiesMemberus-gaap:OtherAggregatedInvestmentsMember2020-12-310001156039us-gaap:FixedMaturitiesMemberus-gaap:OtherAggregatedInvestmentsMember2020-01-012020-12-310001156039us-gaap:FixedMaturitiesMember2020-12-310001156039us-gaap:FixedMaturitiesMember2020-01-012020-12-31antm:securities0001156039us-gaap:CorporateDebtSecuritiesMember2021-06-300001156039us-gaap:ResidentialMortgageBackedSecuritiesMember2021-06-300001156039us-gaap:CorporateDebtSecuritiesMember2020-12-310001156039us-gaap:ResidentialMortgageBackedSecuritiesMember2020-12-310001156039us-gaap:CorporateDebtSecuritiesMember2021-07-012021-09-300001156039us-gaap:ResidentialMortgageBackedSecuritiesMember2021-07-012021-09-300001156039us-gaap:CorporateDebtSecuritiesMember2021-01-012021-09-300001156039us-gaap:ResidentialMortgageBackedSecuritiesMember2021-01-012021-09-300001156039us-gaap:CorporateDebtSecuritiesMember2021-09-300001156039us-gaap:ResidentialMortgageBackedSecuritiesMember2021-09-300001156039us-gaap:CorporateDebtSecuritiesMember2020-06-300001156039us-gaap:ForeignGovernmentDebtMember2020-06-300001156039us-gaap:CorporateDebtSecuritiesMember2019-12-310001156039us-gaap:ForeignGovernmentDebtMember2019-12-310001156039us-gaap:CorporateDebtSecuritiesMember2020-07-012020-09-300001156039us-gaap:ForeignGovernmentDebtMember2020-07-012020-09-300001156039us-gaap:CorporateDebtSecuritiesMember2020-01-012020-09-300001156039us-gaap:ForeignGovernmentDebtMember2020-01-012020-09-300001156039us-gaap:CorporateDebtSecuritiesMember2020-09-300001156039us-gaap:ForeignGovernmentDebtMember2020-09-300001156039us-gaap:FixedMaturitiesMember2021-07-012021-09-300001156039us-gaap:FixedMaturitiesMember2020-07-012020-09-300001156039us-gaap:FixedMaturitiesMember2020-01-012020-09-300001156039us-gaap:ExchangeTradedFundsMember2021-09-300001156039us-gaap:ExchangeTradedFundsMember2020-12-310001156039antm:FixedMaturityMutualFundsMember2021-09-300001156039antm:FixedMaturityMutualFundsMember2020-12-310001156039antm:CommonEquitySecuritiesMember2021-09-300001156039antm:CommonEquitySecuritiesMember2020-12-310001156039us-gaap:PrivateEquityFundsMember2021-09-300001156039us-gaap:PrivateEquityFundsMember2020-12-310001156039us-gaap:EquitySecuritiesMember2021-07-012021-09-300001156039us-gaap:EquitySecuritiesMember2020-07-012020-09-300001156039us-gaap:EquitySecuritiesMember2021-01-012021-09-300001156039us-gaap:EquitySecuritiesMember2020-01-012020-09-300001156039us-gaap:OtherInvestmentsMember2021-07-012021-09-300001156039us-gaap:OtherInvestmentsMember2020-07-012020-09-300001156039us-gaap:OtherInvestmentsMember2021-01-012021-09-300001156039us-gaap:OtherInvestmentsMember2020-01-012020-09-300001156039us-gaap:CashMemberus-gaap:MaturityOvernightMember2021-09-300001156039us-gaap:MaturityOvernightMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-09-300001156039us-gaap:MaturityOvernightMemberus-gaap:OtherAggregatedInvestmentsMember2021-09-300001156039us-gaap:MaturityOvernightMember2021-09-300001156039us-gaap:CashFlowHedgingMember2021-09-300001156039us-gaap:CashFlowHedgingMember2020-12-310001156039us-gaap:FairValueInputsLevel1Member2021-09-300001156039us-gaap:FairValueInputsLevel2Member2021-09-300001156039us-gaap:FairValueInputsLevel3Member2021-09-300001156039us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FixedMaturitiesMember2021-09-300001156039us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FixedMaturitiesMember2021-09-300001156039us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FixedMaturitiesMemberus-gaap:FairValueInputsLevel3Member2021-09-300001156039us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FixedMaturitiesMember2021-09-300001156039us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FixedMaturitiesMember2021-09-300001156039us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FixedMaturitiesMemberus-gaap:FairValueInputsLevel3Member2021-09-300001156039us-gaap:ForeignGovernmentDebtMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FixedMaturitiesMember2021-09-300001156039us-gaap:ForeignGovernmentDebtMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FixedMaturitiesMember2021-09-300001156039us-gaap:ForeignGovernmentDebtMemberus-gaap:FixedMaturitiesMemberus-gaap:FairValueInputsLevel3Member2021-09-300001156039us-gaap:USStatesAndPoliticalSubdivisionsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FixedMaturitiesMember2021-09-300001156039us-gaap:FairValueInputsLevel2Memberus-gaap:USStatesAndPoliticalSubdivisionsMemberus-gaap:FixedMaturitiesMember2021-09-300001156039us-gaap:USStatesAndPoliticalSubdivisionsMemberus-gaap:FixedMaturitiesMemberus-gaap:FairValueInputsLevel3Member2021-09-300001156039us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FixedMaturitiesMember2021-09-300001156039us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FixedMaturitiesMember2021-09-300001156039us-gaap:CorporateDebtSecuritiesMemberus-gaap:FixedMaturitiesMemberus-gaap:FairValueInputsLevel3Member2021-09-300001156039us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FixedMaturitiesMember2021-09-300001156039us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FixedMaturitiesMember2021-09-300001156039us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FixedMaturitiesMemberus-gaap:FairValueInputsLevel3Member2021-09-300001156039us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FixedMaturitiesMember2021-09-300001156039us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FixedMaturitiesMember2021-09-300001156039us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FixedMaturitiesMemberus-gaap:FairValueInputsLevel3Member2021-09-300001156039us-gaap:FairValueInputsLevel1Memberus-gaap:FixedMaturitiesMemberus-gaap:OtherDebtSecuritiesMember2021-09-300001156039us-gaap:FairValueInputsLevel2Memberus-gaap:FixedMaturitiesMemberus-gaap:OtherDebtSecuritiesMember2021-09-300001156039us-gaap:FixedMaturitiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:OtherDebtSecuritiesMember2021-09-300001156039us-gaap:FixedMaturitiesMemberus-gaap:OtherDebtSecuritiesMember2021-09-300001156039us-gaap:FixedMaturitiesMemberus-gaap:FairValueInputsLevel1Member2021-09-300001156039us-gaap:FairValueInputsLevel2Memberus-gaap:FixedMaturitiesMember2021-09-300001156039us-gaap:FixedMaturitiesMemberus-gaap:FairValueInputsLevel3Member2021-09-300001156039us-gaap:FairValueInputsLevel1Memberus-gaap:ExchangeTradedFundsMemberus-gaap:EquitySecuritiesMember2021-09-300001156039us-gaap:FairValueInputsLevel2Memberus-gaap:ExchangeTradedFundsMemberus-gaap:EquitySecuritiesMember2021-09-300001156039us-gaap:ExchangeTradedFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMember2021-09-300001156039us-gaap:ExchangeTradedFundsMemberus-gaap:EquitySecuritiesMember2021-09-300001156039antm:CommonEquitySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMember2021-09-300001156039antm:CommonEquitySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMember2021-09-300001156039antm:CommonEquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMember2021-09-300001156039antm:CommonEquitySecuritiesMemberus-gaap:EquitySecuritiesMember2021-09-300001156039us-gaap:PrivateEquityFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMember2021-09-300001156039us-gaap:PrivateEquityFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMember2021-09-300001156039us-gaap:PrivateEquityFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMember2021-09-300001156039us-gaap:PrivateEquityFundsMemberus-gaap:EquitySecuritiesMember2021-09-300001156039us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMember2021-09-300001156039us-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMember2021-09-300001156039us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMember2021-09-300001156039us-gaap:EquitySecuritiesMember2021-09-300001156039antm:CommonEquitySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:OtherInvestmentsMember2021-09-300001156039antm:CommonEquitySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:OtherInvestmentsMember2021-09-300001156039antm:CommonEquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:OtherInvestmentsMember2021-09-300001156039antm:CommonEquitySecuritiesMemberus-gaap:OtherInvestmentsMember2021-09-300001156039us-gaap:FairValueInputsLevel1Memberus-gaap:DerivativeMember2021-09-300001156039us-gaap:FairValueInputsLevel2Memberus-gaap:DerivativeMember2021-09-300001156039us-gaap:FairValueInputsLevel3Memberus-gaap:DerivativeMember2021-09-300001156039us-gaap:DerivativeMember2021-09-300001156039us-gaap:FairValueInputsLevel1Member2020-12-310001156039us-gaap:FairValueInputsLevel2Member2020-12-310001156039us-gaap:FairValueInputsLevel3Member2020-12-310001156039us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FixedMaturitiesMember2020-12-310001156039us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FixedMaturitiesMember2020-12-310001156039us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FixedMaturitiesMemberus-gaap:FairValueInputsLevel3Member2020-12-310001156039us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FixedMaturitiesMember2020-12-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FixedMaturitiesMember2020-12-310001156039us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FixedMaturitiesMemberus-gaap:FairValueInputsLevel3Member2020-12-310001156039us-gaap:ForeignGovernmentDebtMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FixedMaturitiesMember2020-12-310001156039us-gaap:ForeignGovernmentDebtMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FixedMaturitiesMember2020-12-310001156039us-gaap:ForeignGovernmentDebtMemberus-gaap:FixedMaturitiesMemberus-gaap:FairValueInputsLevel3Member2020-12-310001156039us-gaap:USStatesAndPoliticalSubdivisionsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FixedMaturitiesMember2020-12-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:USStatesAndPoliticalSubdivisionsMemberus-gaap:FixedMaturitiesMember2020-12-310001156039us-gaap:USStatesAndPoliticalSubdivisionsMemberus-gaap:FixedMaturitiesMemberus-gaap:FairValueInputsLevel3Member2020-12-310001156039us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FixedMaturitiesMember2020-12-310001156039us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FixedMaturitiesMember2020-12-310001156039us-gaap:CorporateDebtSecuritiesMemberus-gaap:FixedMaturitiesMemberus-gaap:FairValueInputsLevel3Member2020-12-310001156039us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FixedMaturitiesMember2020-12-310001156039us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FixedMaturitiesMember2020-12-310001156039us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FixedMaturitiesMemberus-gaap:FairValueInputsLevel3Member2020-12-310001156039us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FixedMaturitiesMember2020-12-310001156039us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FixedMaturitiesMember2020-12-310001156039us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FixedMaturitiesMemberus-gaap:FairValueInputsLevel3Member2020-12-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:FixedMaturitiesMemberus-gaap:OtherDebtSecuritiesMember2020-12-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:FixedMaturitiesMemberus-gaap:OtherDebtSecuritiesMember2020-12-310001156039us-gaap:FixedMaturitiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:OtherDebtSecuritiesMember2020-12-310001156039us-gaap:FixedMaturitiesMemberus-gaap:OtherDebtSecuritiesMember2020-12-310001156039us-gaap:FixedMaturitiesMemberus-gaap:FairValueInputsLevel1Member2020-12-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:FixedMaturitiesMember2020-12-310001156039us-gaap:FixedMaturitiesMemberus-gaap:FairValueInputsLevel3Member2020-12-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:ExchangeTradedFundsMemberus-gaap:EquitySecuritiesMember2020-12-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:ExchangeTradedFundsMemberus-gaap:EquitySecuritiesMember2020-12-310001156039us-gaap:ExchangeTradedFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMember2020-12-310001156039us-gaap:ExchangeTradedFundsMemberus-gaap:EquitySecuritiesMember2020-12-310001156039antm:FixedMaturityMutualFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMember2020-12-310001156039antm:FixedMaturityMutualFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMember2020-12-310001156039antm:FixedMaturityMutualFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMember2020-12-310001156039antm:FixedMaturityMutualFundsMemberus-gaap:EquitySecuritiesMember2020-12-310001156039antm:CommonEquitySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMember2020-12-310001156039antm:CommonEquitySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMember2020-12-310001156039antm:CommonEquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMember2020-12-310001156039antm:CommonEquitySecuritiesMemberus-gaap:EquitySecuritiesMember2020-12-310001156039us-gaap:PrivateEquityFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMember2020-12-310001156039us-gaap:PrivateEquityFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMember2020-12-310001156039us-gaap:PrivateEquityFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMember2020-12-310001156039us-gaap:PrivateEquityFundsMemberus-gaap:EquitySecuritiesMember2020-12-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMember2020-12-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMember2020-12-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMember2020-12-310001156039us-gaap:EquitySecuritiesMember2020-12-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:DerivativeMember2020-12-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:DerivativeMember2020-12-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:DerivativeMember2020-12-310001156039us-gaap:DerivativeMember2020-12-310001156039us-gaap:OtherDebtSecuritiesMember2021-06-300001156039us-gaap:EquitySecuritiesMember2021-06-300001156039us-gaap:OtherDebtSecuritiesMember2021-07-012021-09-300001156039us-gaap:EquitySecuritiesMember2021-07-012021-09-300001156039us-gaap:OtherDebtSecuritiesMember2021-09-300001156039us-gaap:EquitySecuritiesMember2021-09-300001156039us-gaap:ResidentialMortgageBackedSecuritiesMember2020-06-300001156039us-gaap:OtherDebtSecuritiesMember2020-06-300001156039us-gaap:EquitySecuritiesMember2020-06-300001156039us-gaap:ResidentialMortgageBackedSecuritiesMember2020-07-012020-09-300001156039us-gaap:OtherDebtSecuritiesMember2020-07-012020-09-300001156039us-gaap:EquitySecuritiesMember2020-07-012020-09-300001156039us-gaap:ResidentialMortgageBackedSecuritiesMember2020-09-300001156039us-gaap:OtherDebtSecuritiesMember2020-09-300001156039us-gaap:EquitySecuritiesMember2020-09-300001156039us-gaap:OtherDebtSecuritiesMember2020-12-310001156039us-gaap:EquitySecuritiesMember2020-12-310001156039us-gaap:OtherDebtSecuritiesMember2021-01-012021-09-300001156039us-gaap:EquitySecuritiesMember2021-01-012021-09-300001156039us-gaap:ResidentialMortgageBackedSecuritiesMember2019-12-310001156039us-gaap:OtherDebtSecuritiesMember2019-12-310001156039us-gaap:EquitySecuritiesMember2019-12-310001156039us-gaap:ResidentialMortgageBackedSecuritiesMember2020-01-012020-09-300001156039us-gaap:OtherDebtSecuritiesMember2020-01-012020-09-300001156039us-gaap:EquitySecuritiesMember2020-01-012020-09-300001156039us-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:OtherInvestmentsMember2021-09-300001156039us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:OtherInvestmentsMember2021-09-300001156039us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherInvestmentsMember2021-09-300001156039us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:OtherInvestmentsMember2021-09-300001156039us-gaap:OtherInvestmentsMember2021-09-300001156039us-gaap:FairValueMeasurementsNonrecurringMember2021-09-300001156039us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-09-300001156039us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-09-300001156039us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-09-300001156039us-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:OtherInvestmentsMember2020-12-310001156039us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:OtherInvestmentsMember2020-12-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001156039us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:OtherInvestmentsMember2020-12-310001156039us-gaap:OtherInvestmentsMember2020-12-310001156039us-gaap:FairValueMeasurementsNonrecurringMember2020-12-310001156039us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-12-310001156039us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-12-310001156039antm:CommercialSpecialtyBusinessSegmentMember2020-12-310001156039antm:GovernmentBusinessSegmentMember2020-12-310001156039antm:OtherSegmentMember2020-12-310001156039antm:CommercialSpecialtyBusinessSegmentMember2021-09-300001156039antm:GovernmentBusinessSegmentMember2021-09-300001156039antm:OtherSegmentMember2021-09-300001156039antm:CommercialSpecialtyBusinessSegmentMember2021-01-012021-09-300001156039antm:GovernmentBusinessSegmentMember2021-01-012021-09-300001156039antm:OtherSegmentMember2021-01-012021-09-300001156039antm:CommercialSpecialtyBusinessSegmentMemberus-gaap:ShortDurationInsuranceContractAccidentYear2019Member2021-09-300001156039us-gaap:ShortDurationInsuranceContractAccidentYear2020Memberantm:CommercialSpecialtyBusinessSegmentMember2021-09-300001156039us-gaap:ShortDurationInsuranceContractAccidentYear2021Memberantm:CommercialSpecialtyBusinessSegmentMember2021-09-300001156039antm:GovernmentBusinessSegmentMemberus-gaap:ShortDurationInsuranceContractAccidentYear2019Member2021-09-300001156039us-gaap:ShortDurationInsuranceContractAccidentYear2020Memberantm:GovernmentBusinessSegmentMember2021-09-300001156039us-gaap:ShortDurationInsuranceContractAccidentYear2021Memberantm:GovernmentBusinessSegmentMember2021-09-300001156039antm:OtherSegmentMemberus-gaap:ShortDurationInsuranceContractAccidentYear2019Member2021-09-300001156039antm:OtherSegmentMemberus-gaap:ShortDurationInsuranceContractAccidentYear2020Member2021-09-300001156039antm:OtherSegmentMemberus-gaap:ShortDurationInsuranceContractAccidentYear2021Member2021-09-300001156039antm:CommercialSpecialtyBusinessSegmentMember2019-12-310001156039antm:GovernmentBusinessSegmentMember2019-12-310001156039antm:OtherSegmentMember2019-12-310001156039antm:CommercialSpecialtyBusinessSegmentMember2020-09-300001156039antm:GovernmentBusinessSegmentMember2020-09-300001156039antm:OtherSegmentMember2020-09-300001156039antm:CommercialSpecialtyBusinessSegmentMember2020-01-012020-09-300001156039antm:GovernmentBusinessSegmentMember2020-01-012020-09-300001156039antm:OtherSegmentMember2020-01-012020-09-300001156039antm:CommercialSpecialtyBusinessSegmentMember2021-01-012021-03-310001156039antm:CommercialSpecialtyBusinessSegmentMember2021-04-012021-06-300001156039antm:CommercialSpecialtyBusinessSegmentMember2021-07-012021-09-300001156039antm:GovernmentBusinessSegmentMember2021-01-012021-03-310001156039antm:GovernmentBusinessSegmentMember2021-04-012021-06-300001156039antm:GovernmentBusinessSegmentMember2021-07-012021-09-300001156039antm:OtherSegmentMember2021-01-012021-03-310001156039antm:OtherSegmentMember2021-04-012021-06-300001156039antm:OtherSegmentMember2021-07-012021-09-300001156039antm:CommercialSpecialtyBusinessSegmentMember2020-01-012020-03-310001156039antm:CommercialSpecialtyBusinessSegmentMember2020-04-012020-06-300001156039antm:CommercialSpecialtyBusinessSegmentMember2020-07-012020-09-300001156039antm:GovernmentBusinessSegmentMember2020-01-012020-03-310001156039antm:GovernmentBusinessSegmentMember2020-04-012020-06-300001156039antm:GovernmentBusinessSegmentMember2020-07-012020-09-300001156039antm:OtherSegmentMember2020-01-012020-03-310001156039antm:OtherSegmentMember2020-04-012020-06-300001156039antm:OtherSegmentMember2020-07-012020-09-300001156039antm:SeniorUnsecuredNotesMember2021-09-300001156039antm:SeniorUnsecuredNotesMember2020-12-310001156039antm:ThreePointSevenZeroZeroPercentDueTwoThousandTwentyOneMember2021-05-150001156039antm:ThreePointSevenZeroZeroPercentDueTwoThousandTwentyOneMember2021-05-152021-05-150001156039antm:PointFourFiveZeroPercentDueTwoThousandTwentyThreeMember2021-03-170001156039antm:OnePointFiveZeroPercentDueTwoThousandTwentySixMember2021-03-170001156039antm:TwoPointFiveFiveZeroPercentDueTwoThousandThirtyOneMember2021-03-170001156039antm:ThreePointSixZeroPercentDueTwoThousandFiftyOneMember2021-03-170001156039antm:SurplusNotesMember2021-09-300001156039us-gaap:RevolvingCreditFacilityMemberantm:A5YearFacilityMember2021-09-300001156039antm:New364DayFacilityMemberus-gaap:RevolvingCreditFacilityMember2021-09-300001156039us-gaap:RevolvingCreditFacilityMember2021-01-012021-09-300001156039us-gaap:LineOfCreditMember2021-09-300001156039us-gaap:CommercialPaperMember2021-09-300001156039us-gaap:CommercialPaperMember2020-12-310001156039us-gaap:ConvertibleDebtMember2021-07-012021-09-300001156039us-gaap:ConvertibleDebtMember2021-01-012021-09-300001156039us-gaap:ConvertibleDebtMember2021-09-300001156039us-gaap:FederalHomeLoanBankAdvancesMember2021-09-300001156039us-gaap:FederalHomeLoanBankAdvancesMember2020-12-310001156039antm:SurplusNotesMember2020-12-310001156039srt:MinimumMember2021-09-300001156039srt:MaximumMember2021-09-300001156039antm:BCBSAntitrustLitigationMember2020-12-310001156039antm:BCBSAntitrustLitigationMember2021-09-300001156039antm:AnthemInc.v.ExpressScriptsInc.Memberantm:PharmacypricingMember2021-01-012021-09-300001156039antm:AnthemInc.v.ExpressScriptsInc.Memberantm:OperationalMember2021-01-012021-09-300001156039antm:AnthemInc.v.ExpressScriptsInc.Member2021-01-012021-09-300001156039us-gaap:SubsequentEventMember2021-10-190001156039us-gaap:SubsequentEventMember2021-12-212021-12-2100011560392021-01-260001156039antm:A2020to2022Memberus-gaap:RestrictedStockUnitsRSUMember2021-01-012021-09-300001156039antm:A2017to2019Memberus-gaap:RestrictedStockUnitsRSUMember2021-01-012021-09-30antm:segment0001156039antm:CommercialSpecialtyMemberantm:UnaffiliatedMember2021-07-012021-09-300001156039antm:GovernmentBusinessSegmentMemberantm:UnaffiliatedMember2021-07-012021-09-300001156039antm:UnaffiliatedMemberantm:IngenioRxSegmentMember2021-07-012021-09-300001156039antm:OtherSegmentMemberantm:UnaffiliatedMember2021-07-012021-09-300001156039antm:UnaffiliatedMember2021-07-012021-09-300001156039antm:AffiliatedMemberantm:IngenioRxSegmentMember2021-07-012021-09-300001156039antm:AffiliatedMemberantm:OtherSegmentMember2021-07-012021-09-300001156039us-gaap:IntersegmentEliminationMember2021-07-012021-09-300001156039antm:AffiliatedMember2021-07-012021-09-300001156039antm:CommercialSpecialtyMember2021-07-012021-09-300001156039antm:GovernmentBusinessSegmentMember2021-07-012021-09-300001156039antm:IngenioRxSegmentMember2021-07-012021-09-300001156039antm:OtherSegmentMember2021-07-012021-09-300001156039antm:CommercialSpecialtyMemberantm:UnaffiliatedMember2020-07-012020-09-300001156039antm:GovernmentBusinessSegmentMemberantm:UnaffiliatedMember2020-07-012020-09-300001156039antm:UnaffiliatedMemberantm:IngenioRxSegmentMember2020-07-012020-09-300001156039antm:OtherSegmentMemberantm:UnaffiliatedMember2020-07-012020-09-300001156039antm:UnaffiliatedMember2020-07-012020-09-300001156039antm:CommercialSpecialtyMemberantm:AffiliatedMember2020-07-012020-09-300001156039antm:GovernmentBusinessSegmentMemberantm:AffiliatedMember2020-07-012020-09-300001156039antm:AffiliatedMemberantm:IngenioRxSegmentMember2020-07-012020-09-300001156039antm:AffiliatedMemberantm:OtherSegmentMember2020-07-012020-09-300001156039us-gaap:IntersegmentEliminationMember2020-07-012020-09-300001156039antm:AffiliatedMember2020-07-012020-09-300001156039antm:CommercialSpecialtyMember2020-07-012020-09-300001156039antm:GovernmentBusinessSegmentMember2020-07-012020-09-300001156039antm:IngenioRxSegmentMember2020-07-012020-09-300001156039antm:OtherSegmentMember2020-07-012020-09-300001156039antm:CommercialSpecialtyMemberantm:UnaffiliatedMember2021-01-012021-09-300001156039antm:GovernmentBusinessSegmentMemberantm:UnaffiliatedMember2021-01-012021-09-300001156039antm:UnaffiliatedMemberantm:IngenioRxSegmentMember2021-01-012021-09-300001156039antm:OtherSegmentMemberantm:UnaffiliatedMember2021-01-012021-09-300001156039antm:UnaffiliatedMember2021-01-012021-09-300001156039antm:CommercialSpecialtyMemberantm:AffiliatedMember2021-01-012021-09-300001156039antm:GovernmentBusinessSegmentMemberantm:AffiliatedMember2021-01-012021-09-300001156039antm:AffiliatedMemberantm:IngenioRxSegmentMember2021-01-012021-09-300001156039antm:AffiliatedMemberantm:OtherSegmentMember2021-01-012021-09-300001156039us-gaap:IntersegmentEliminationMember2021-01-012021-09-300001156039antm:AffiliatedMember2021-01-012021-09-300001156039antm:CommercialSpecialtyMember2021-01-012021-09-300001156039antm:GovernmentBusinessSegmentMember2021-01-012021-09-300001156039antm:IngenioRxSegmentMember2021-01-012021-09-300001156039antm:OtherSegmentMember2021-01-012021-09-300001156039antm:CommercialSpecialtyMemberantm:UnaffiliatedMember2020-01-012020-09-300001156039antm:GovernmentBusinessSegmentMemberantm:UnaffiliatedMember2020-01-012020-09-300001156039antm:UnaffiliatedMemberantm:IngenioRxSegmentMember2020-01-012020-09-300001156039antm:OtherSegmentMemberantm:UnaffiliatedMember2020-01-012020-09-300001156039antm:UnaffiliatedMember2020-01-012020-09-300001156039antm:CommercialSpecialtyMemberantm:AffiliatedMember2020-01-012020-09-300001156039antm:GovernmentBusinessSegmentMemberantm:AffiliatedMember2020-01-012020-09-300001156039antm:AffiliatedMemberantm:IngenioRxSegmentMember2020-01-012020-09-300001156039antm:AffiliatedMemberantm:OtherSegmentMember2020-01-012020-09-300001156039us-gaap:IntersegmentEliminationMember2020-01-012020-09-300001156039antm:AffiliatedMember2020-01-012020-09-300001156039antm:CommercialSpecialtyMember2020-01-012020-09-300001156039antm:GovernmentBusinessSegmentMember2020-01-012020-09-300001156039antm:IngenioRxSegmentMember2020-01-012020-09-300001156039antm:OtherSegmentMember2020-01-012020-09-300001156039antm:ManagedCareProductsMemberantm:CommercialSpecialtyBusinessSegmentMember2021-07-012021-09-300001156039antm:ManagedCareProductsMemberantm:CommercialSpecialtyBusinessSegmentMember2020-07-012020-09-300001156039antm:ManagedCareProductsMemberantm:CommercialSpecialtyBusinessSegmentMember2021-01-012021-09-300001156039antm:ManagedCareProductsMemberantm:CommercialSpecialtyBusinessSegmentMember2020-01-012020-09-300001156039antm:CommercialSpecialtyBusinessSegmentMemberantm:ManagedCareServicesMember2021-07-012021-09-300001156039antm:CommercialSpecialtyBusinessSegmentMemberantm:ManagedCareServicesMember2020-07-012020-09-300001156039antm:CommercialSpecialtyBusinessSegmentMemberantm:ManagedCareServicesMember2021-01-012021-09-300001156039antm:CommercialSpecialtyBusinessSegmentMemberantm:ManagedCareServicesMember2020-01-012020-09-300001156039antm:DentalVisionProductsAndServicesMemberantm:CommercialSpecialtyBusinessSegmentMember2021-07-012021-09-300001156039antm:DentalVisionProductsAndServicesMemberantm:CommercialSpecialtyBusinessSegmentMember2020-07-012020-09-300001156039antm:DentalVisionProductsAndServicesMemberantm:CommercialSpecialtyBusinessSegmentMember2021-01-012021-09-300001156039antm:DentalVisionProductsAndServicesMemberantm:CommercialSpecialtyBusinessSegmentMember2020-01-012020-09-300001156039antm:CommercialSpecialtyBusinessSegmentMemberantm:OtherProductsMember2021-07-012021-09-300001156039antm:CommercialSpecialtyBusinessSegmentMemberantm:OtherProductsMember2020-07-012020-09-300001156039antm:CommercialSpecialtyBusinessSegmentMemberantm:OtherProductsMember2021-01-012021-09-300001156039antm:CommercialSpecialtyBusinessSegmentMemberantm:OtherProductsMember2020-01-012020-09-300001156039antm:GovernmentBusinessSegmentMemberantm:ManagedCareProductsMember2021-07-012021-09-300001156039antm:GovernmentBusinessSegmentMemberantm:ManagedCareProductsMember2020-07-012020-09-300001156039antm:GovernmentBusinessSegmentMemberantm:ManagedCareProductsMember2021-01-012021-09-300001156039antm:GovernmentBusinessSegmentMemberantm:ManagedCareProductsMember2020-01-012020-09-300001156039antm:GovernmentBusinessSegmentMemberantm:ManagedCareServicesMember2021-07-012021-09-300001156039antm:GovernmentBusinessSegmentMemberantm:ManagedCareServicesMember2020-07-012020-09-300001156039antm:GovernmentBusinessSegmentMemberantm:ManagedCareServicesMember2021-01-012021-09-300001156039antm:GovernmentBusinessSegmentMemberantm:ManagedCareServicesMember2020-01-012020-09-300001156039antm:IngenioRxSegmentMemberantm:PharmacyproductsandservicesMember2021-07-012021-09-300001156039antm:IngenioRxSegmentMemberantm:PharmacyproductsandservicesMember2020-07-012020-09-300001156039antm:IngenioRxSegmentMemberantm:PharmacyproductsandservicesMember2021-01-012021-09-300001156039antm:IngenioRxSegmentMemberantm:PharmacyproductsandservicesMember2020-01-012020-09-300001156039antm:IngenioRxSegmentMember2021-07-012021-09-300001156039antm:IngenioRxSegmentMember2020-07-012020-09-300001156039antm:IngenioRxSegmentMember2021-01-012021-09-300001156039antm:IngenioRxSegmentMember2020-01-012020-09-300001156039antm:OtherSegmentMemberantm:IntegratedHealthServicesMember2021-07-012021-09-300001156039antm:OtherSegmentMemberantm:IntegratedHealthServicesMember2020-07-012020-09-300001156039antm:OtherSegmentMemberantm:IntegratedHealthServicesMember2021-01-012021-09-300001156039antm:OtherSegmentMemberantm:IntegratedHealthServicesMember2020-01-012020-09-300001156039antm:OtherSegmentMemberantm:OtherProductsMember2021-07-012021-09-300001156039antm:OtherSegmentMemberantm:OtherProductsMember2020-07-012020-09-300001156039antm:OtherSegmentMemberantm:OtherProductsMember2021-01-012021-09-300001156039antm:OtherSegmentMemberantm:OtherProductsMember2020-01-012020-09-300001156039antm:SegmentEliminationsMember2021-07-012021-09-300001156039antm:SegmentEliminationsMember2020-07-012020-09-300001156039antm:SegmentEliminationsMember2021-01-012021-09-300001156039antm:SegmentEliminationsMember2020-01-012020-09-300001156039us-gaap:OtherNoncurrentAssetsMember2021-09-300001156039us-gaap:OtherNoncurrentAssetsMember2020-12-310001156039us-gaap:OtherCurrentLiabilitiesMember2021-09-300001156039us-gaap:OtherCurrentLiabilitiesMember2020-12-310001156039us-gaap:OtherNoncurrentLiabilitiesMember2021-09-300001156039us-gaap:OtherNoncurrentLiabilitiesMember2020-12-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
| | | | | |
☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the Quarterly Period Ended September 30, 2021
OR
| | | | | |
☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission file number: 001-16751
ANTHEM, INC.
(Exact name of registrant as specified in its charter)
| | | | | | | | |
Indiana | | 35-2145715 |
(State or other jurisdiction of incorporation or organization) | | (I.R.S. Employer Identification Number) |
220 Virginia Avenue
Indianapolis, Indiana 46204
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (800) 331-1476
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | | | | | | | |
Title of each class | | Trading symbol(s) | | Name of each exchange on which registered |
Common Stock, $0.01 par value | | ANTM | | New York Stock Exchange |
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act:
| | | | | | | | | | | | | | | | | |
Large accelerated filer | ☒ | | | Accelerated filer | ☐ |
Non-accelerated filer | ☐ | | | Smaller reporting company | ☐ |
Emerging growth company | ☐ | | | | |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of October 14, 2021, 242,714,676 shares of the Registrant’s Common Stock were outstanding.
Anthem, Inc.
Quarterly Report on Form 10-Q
For the Period Ended September 30, 2021
Table of Contents
| | | | | | | | |
| | Page |
PART I. FINANCIAL INFORMATION | |
| | |
ITEM 1. | | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
ITEM 2. | | |
ITEM 3. | | |
ITEM 4. | | |
PART II. OTHER INFORMATION | |
ITEM 1. | | |
ITEM 1A. | | |
ITEM 2. | | |
ITEM 3. | | |
ITEM 4. | | |
ITEM 5. | | |
ITEM 6. | | |
| |
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
Anthem, Inc.
Consolidated Balance Sheets
| | | | | | | | | | | |
| September 30, 2021 | | December 31, 2020 |
(In millions, except share data) | (Unaudited) | | |
Assets | | | |
Current assets: | | | |
Cash and cash equivalents | $ | 5,490 | | | $ | 5,741 | |
Fixed maturity securities (amortized cost of $25,495 and $22,222; allowance for credit losses of $6 and $7) | 26,348 | | | 23,433 | |
Equity securities | 2,119 | | | 1,559 | |
| | | |
| | | |
Premium receivables | 6,008 | | | 5,279 | |
Self-funded receivables | 3,349 | | | 2,849 | |
Other receivables | 3,450 | | | 2,830 | |
| | | |
| | | |
Other current assets | 5,140 | | | 4,060 | |
Total current assets | 51,904 | | | 45,751 | |
Long-term investments: | | | |
Fixed maturity securities (amortized cost of $606 and $532; allowance for credit losses of $0 and $0) | 625 | | | 562 | |
| | | |
Other invested assets | 4,959 | | | 4,285 | |
Property and equipment, net | 3,835 | | | 3,483 | |
Goodwill | 24,184 | | | 21,691 | |
Other intangible assets | 10,749 | | | 9,405 | |
Other noncurrent assets | 1,804 | | | 1,438 | |
Total assets | $ | 98,060 | | | $ | 86,615 | |
| | | |
Liabilities and equity | | | |
Liabilities | | | |
Current liabilities: | | | |
| | | |
Medical claims payable | $ | 13,562 | | | $ | 11,359 | |
| | | |
Other policyholder liabilities | 5,201 | | | 4,590 | |
| | | |
Unearned income | 954 | | | 1,259 | |
Accounts payable and accrued expenses | 5,960 | | | 5,493 | |
| | | |
| | | |
| | | |
Short-term borrowings | 175 | | | — | |
Current portion of long-term debt | 849 | | | 700 | |
Other current liabilities | 8,461 | | | 6,052 | |
Total current liabilities | 35,162 | | | 29,453 | |
Long-term debt, less current portion | 21,761 | | | 19,335 | |
Reserves for future policy benefits | 788 | | | 794 | |
Deferred tax liabilities, net | 2,629 | | | 2,019 | |
Other noncurrent liabilities | 1,912 | | | 1,815 | |
Total liabilities | 62,252 | | | 53,416 | |
| | | |
Commitments and contingencies – Note 11 | | | |
| | | |
Shareholders’ equity | | | |
Preferred stock, without par value, shares authorized – 100,000,000; shares issued and outstanding – none | — | | | — | |
Common stock, par value $0.01, shares authorized – 900,000,000; shares issued and outstanding – 242,847,676 and 245,401,430 | 2 | | | 3 | |
Additional paid-in capital | 9,138 | | | 9,244 | |
Retained earnings | 26,700 | | | 23,802 | |
Accumulated other comprehensive (loss) income | (103) | | | 150 | |
Total shareholders’ equity | 35,737 | | | 33,199 | |
Noncontrolling interests | 71 | | | — | |
Total equity | 35,808 | | | 33,199 | |
Total liabilities and equity | $ | 98,060 | | | $ | 86,615 | |
See accompanying notes.
Anthem, Inc.
Consolidated Statements of Income
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended September 30 | | Nine Months Ended September 30 |
(In millions, except per share data) | 2021 | | 2020 | | 2021 | | 2020 |
Revenues | | | | | | | |
Premiums | $ | 30,395 | | | $ | 26,392 | | | $ | 86,604 | | | $ | 77,001 | |
Product revenue | 3,353 | | | 2,598 | | | 9,132 | | | 7,485 | |
Administrative fees and other revenue | 1,800 | | | 1,659 | | | 5,189 | | | 4,789 | |
Total operating revenue | 35,548 | | | 30,649 | | | 100,925 | | | 89,275 | |
Net investment income | 335 | | | 280 | | | 1,026 | | | 591 | |
Net realized (losses) gains on financial instruments | (61) | | | 229 | | | 107 | | | 177 | |
Total revenues | 35,822 | | | 31,158 | | | 102,058 | | | 90,043 | |
Expenses | | | | | | | |
Benefit expense | 26,645 | | | 22,921 | | | 75,107 | | | 63,957 | |
Cost of products sold | 2,898 | | | 2,222 | | | 7,825 | | | 6,431 | |
Selling, general and administrative expense | 3,946 | | | 5,305 | | | 11,692 | | | 13,132 | |
Interest expense | 201 | | | 198 | | | 598 | | | 593 | |
Amortization of other intangible assets | 136 | | | 93 | | | 306 | | | 269 | |
Loss on extinguishment of debt | — | | | 30 | | | 5 | | | 34 | |
| | | | | | | |
Total expenses | 33,826 | | | 30,769 | | | 95,533 | | | 84,416 | |
Income before income tax expense | 1,996 | | | 389 | | | 6,525 | | | 5,627 | |
Income tax expense | 494 | | | 167 | | | 1,555 | | | 1,606 | |
| | | | | | | |
| | | | | | | |
Net income | 1,502 | | | 222 | | | 4,970 | | | 4,021 | |
Net loss (income) attributable to noncontrolling interests | 7 | | | — | | | (3) | | | — | |
Shareholders’ net income | $ | 1,509 | | | $ | 222 | | | $ | 4,967 | | | $ | 4,021 | |
Shareholders’ net income per share | | | | | | | |
| | | | | | | |
| | | | | | | |
Basic | $ | 6.20 | | | $ | 0.88 | | | $ | 20.33 | | | $ | 15.96 | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Diluted | $ | 6.13 | | | $ | 0.87 | | | $ | 20.09 | | | $ | 15.75 | |
Dividends per share | $ | 1.13 | | | $ | 0.95 | | | $ | 3.39 | | | $ | 2.85 | |
See accompanying notes.
Anthem, Inc.
Consolidated Statements of Comprehensive Income
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended September 30 | | Nine Months Ended September 30 |
(In millions) | | 2021 | | 2020 | | 2021 | | 2020 |
Net income | | $ | 1,502 | | | $ | 222 | | | $ | 4,970 | | | $ | 4,021 | |
Other comprehensive (loss) income, net of tax: | | | | | | | | |
Change in net unrealized losses/gains on investments | | (97) | | | 113 | | | (284) | | | 154 | |
Change in non-credit component of impairment losses on investments | | (1) | | | 16 | | | 1 | | | (6) | |
Change in net unrealized gains/losses on cash flow hedges | | 4 | | | 4 | | | 10 | | | 10 | |
Change in net periodic pension and postretirement costs | | 8 | | | 8 | | | 26 | | | 25 | |
Foreign currency translation adjustments | | (1) | | | 1 | | | (7) | | | 1 | |
Other comprehensive (loss) income | | (87) | | | 142 | | | (254) | | | 184 | |
Net loss (income) attributable to noncontrolling interests | | 7 | | | — | | | (3) | | | — | |
Other comprehensive loss attributable to noncontrolling interests | | 1 | | | — | | | 1 | | | — | |
Total shareholders’ comprehensive income | | $ | 1,423 | | | $ | 364 | | | $ | 4,714 | | | $ | 4,205 | |
See accompanying notes.
Anthem, Inc.
Consolidated Statements of Cash Flows
(Unaudited)
| | | | | | | | | | | |
| Nine Months Ended September 30 |
(In millions) | 2021 | | 2020 |
Operating activities | | | |
Net income | $ | 4,970 | | | $ | 4,021 | |
Adjustments to reconcile net income to net cash provided by operating activities: | | | |
Net realized gains on financial instruments | (107) | | | (177) | |
Depreciation and amortization | 942 | | | 864 | |
| | | |
| | | |
| | | |
| | | |
Deferred income taxes | 114 | | | (102) | |
| | | |
| | | |
Impairment of property and equipment | — | | | 195 | |
Share-based compensation | 196 | | | 214 | |
| | | |
Changes in operating assets and liabilities: | | | |
Receivables, net | (1,751) | | | (845) | |
Other invested assets | (56) | | | 6 | |
Other assets | (470) | | | (988) | |
Policy liabilities | 2,328 | | | 1,624 | |
Unearned income | (308) | | | (95) | |
Accounts payable and other liabilities | 1,093 | | | 1,953 | |
| | | |
| | | |
Income taxes | 168 | | | 104 | |
Other, net | (427) | | | 101 | |
Net cash provided by operating activities | 6,692 | | | 6,875 | |
Investing activities | | | |
| | | |
| | | |
| | | |
Purchases of investments | (15,130) | | | (16,708) | |
Proceeds from sale of investments | 8,339 | | | 8,739 | |
Maturities, calls and redemptions from investments | 3,388 | | | 3,763 | |
| | | |
| | | |
| | | |
| | | |
| | | |
Changes in securities lending collateral | (1,030) | | | (668) | |
Purchases of subsidiaries, net of cash acquired | (3,442) | | | (1,973) | |
| | | |
Purchases of property and equipment | (747) | | | (743) | |
| | | |
Other, net | (50) | | | (39) | |
Net cash used in investing activities | (8,672) | | | (7,629) | |
Financing activities | | | |
Net repayments of commercial paper borrowings | (150) | | | (400) | |
Proceeds from long-term borrowings | 3,462 | | | 2,485 | |
Repayments of long-term borrowings | (954) | | | (964) | |
Proceeds from short-term borrowings | 175 | | | 970 | |
Repayments of short-term borrowings | — | | | (1,520) | |
Changes in securities lending payable | 1,030 | | | 668 | |
| | | |
| | | |
| | | |
| | | |
Repurchase and retirement of common stock | (1,378) | | | (1,342) | |
| | | |
Cash dividends | (831) | | | (720) | |
Proceeds from issuance of common stock under employee stock plans | 161 | | | 112 | |
Taxes paid through withholding of common stock under employee stock plans | (101) | | | (112) | |
| | | |
Other, net | 324 | | | 623 | |
Net cash provided by (used in) financing activities | 1,738 | | | (200) | |
Effect of foreign exchange rates on cash and cash equivalents | (9) | | | 1 | |
Change in cash and cash equivalents | (251) | | | (953) | |
Cash and cash equivalents at beginning of period | 5,741 | | | 4,937 | |
Cash and cash equivalents at end of period | $ | 5,490 | | | $ | 3,984 | |
See accompanying notes.
Anthem, Inc.
Consolidated Statements of Shareholders’ Equity
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Nine Months Ended September 30, 2021 | | | | | | | | | | | | | | |
| Common Stock | | Additional Paid-in Capital | | Retained Earnings | | Accumulated Other Comprehensive Income (Loss) | | Noncontrolling Interests | | Total Equity | | | | | | | | | | | | | | |
(In millions) | Number of Shares | | Par Value | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
January 1, 2021 | 245.4 | | | $ | 3 | | | $ | 9,244 | | | $ | 23,802 | | | $ | 150 | | | $ | — | | | $ | 33,199 | | | | | | | | | | | | | | | |
Net income | — | | | — | | | — | | | 1,665 | | | — | | | 2 | | | 1,667 | | | | | | | | | | | | | | | |
Other comprehensive loss | — | | | — | | | — | | | — | | | (345) | | | (2) | | | (347) | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Noncontrolling interests adjustment | — | | | — | | | — | | | — | | | — | | | 65 | | | 65 | | | | | | | | | | | | | | | |
Repurchase and retirement of common stock | (1.4) | | | (1) | | | (53) | | | (393) | | | — | | | — | | | (447) | | | | | | | | | | | | | | | |
Dividends and dividend equivalents | — | | | — | | | — | | | (281) | | | — | | | — | | | (281) | | | | | | | | | | | | | | | |
Issuance of common stock under employee stock plans, net of related tax benefits | 0.9 | | | — | | | 62 | | | — | | | — | | | — | | | 62 | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
March 31, 2021 | 244.9 | | | 2 | | | 9,253 | | | 24,793 | | | (195) | | | 65 | | | 33,918 | | | | | | | | | | | | | | | |
Net income | — | | | — | | | — | | | 1,793 | | | — | | | 8 | | | 1,801 | | | | | | | | | | | | | | | |
Other comprehensive income | — | | | — | | | — | | | — | | | 178 | | | 2 | | | 180 | | | | | | | | | | | | | | | |
Noncontrolling interests adjustment | — | | | — | | | — | | | — | | | — | | | 3 | | | 3 | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Repurchase and retirement of common stock | (1.3) | | | — | | | (47) | | | (433) | | | — | | | — | | | (480) | | | | | | | | | | | | | | | |
Dividends and dividend equivalents | — | | | — | | | — | | | (279) | | | — | | | — | | | (279) | | | | | | | | | | | | | | | |
Issuance of common stock under employee stock plans, net of related tax benefits | 0.3 | | | — | | | 119 | | | — | | | — | | | — | | | 119 | | | | | | | | | | | | | | | |
Convertible debenture repurchases and conversions | — | | | — | | | (216) | | | — | | | — | | | — | | | (216) | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
June 30, 2021 | 243.9 | | | 2 | | | 9,109 | | | 25,874 | | | (17) | | | 78 | | | 35,046 | | | | | | | | | | | | | | | |
Net income (loss) | — | | | — | | | — | | | 1,509 | | | — | | | (7) | | | 1,502 | | | | | | | | | | | | | | | |
Other comprehensive loss | — | | | — | | | — | | | — | | | (86) | | | (1) | | | (87) | | | | | | | | | | | | | | | |
Noncontrolling interest adjustment | — | | | — | | | — | | | — | | | — | | | 1 | | | 1 | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Repurchase and retirement of common stock | (1.2) | | | — | | | (44) | | | (407) | | | — | | | — | | | (451) | | | | | | | | | | | | | | | |
Dividends and dividend equivalents | — | | | — | | | — | | | (276) | | | — | | | — | | | (276) | | | | | | | | | | | | | | | |
Issuance of common stock under employee stock plans, net of related tax benefits | 0.1 | | | — | | | 75 | | | — | | | — | | | — | | | 75 | | | | | | | | | | | | | | | |
Convertible debenture repurchases and conversions | — | | | — | | | (2) | | | — | | | — | | | — | | | (2) | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
September 30, 2021 | 242.8 | | | $ | 2 | | | $ | 9,138 | | | $ | 26,700 | | | $ | (103) | | | $ | 71 | | | $ | 35,808 | | | | | | | | | | | | | | | |
See accompanying notes.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Anthem, Inc. Consolidated Statements of Shareholders’ Equity (continued) (Unaudited) |
| | | | | | | | | | | | | |
| Nine Months Ended September 30, 2020 |
| Common Stock | | Additional Paid-in Capital | | Retained Earnings | | Accumulated Other Comprehensive (Loss) Income | | Noncontrolling Interests | | Total Equity |
(In millions) | Number of Shares | | Par Value | | |
December 31, 2019 (audited) | 252.9 | | | $ | 3 | | | $ | 9,448 | | | $ | 22,573 | | | $ | (296) | | | $ | — | | | $ | 31,728 | |
Adoption of Accounting Standards Update No. 2016-13 | — | | | — | | | — | | | (35) | | | — | | | — | | | (35) | |
January 1, 2020 | 252.9 | | | 3 | | | 9,448 | | | 22,538 | | | (296) | | | — | | | 31,693 | |
Net income | — | | | — | | | — | | | 1,523 | | | — | | | — | | | 1,523 | |
Other comprehensive loss | — | | | — | | | — | | | — | | | (712) | | | — | | | (712) | |
| | | | | | | | | | | | | |
Repurchase and retirement of common stock | (1.9) | | | — | | | (71) | | | (458) | | | — | | | — | | | (529) | |
Dividends and dividend equivalents | — | | | — | | | — | | | (243) | | | — | | | — | | | (243) | |
Issuance of common stock under employee stock plans, net of related tax benefits | 1.0 | | | — | | | 3 | | | — | | | — | | | — | | | 3 | |
Convertible debenture repurchases and conversions | — | | | — | | | (42) | | | — | | | — | | | — | | | (42) | |
March 31, 2020 | 252.0 | | | 3 | | | 9,338 | | | 23,360 | | | (1,008) | | | — | | | 31,693 | |
Net income | — | | | — | | | — | | | 2,276 | | | — | | | — | | | 2,276 | |
Other comprehensive income | — | | | — | | | — | | | — | | | 754 | | | — | | | 754 | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
Repurchase and retirement of common stock | (0.2) | | | — | | | (9) | | | (46) | | | — | | | — | | | (55) | |
Dividends and dividend equivalents | — | | | — | | | — | | | (244) | | | — | | | — | | | (244) | |
Issuance of common stock under employee stock plans, net of related tax benefits | 0.3 | | | — | | | 113 | | | — | | | — | | | — | | | 113 | |
Convertible debenture repurchases and conversions | — | | | — | | | (82) | | | — | | | — | | | — | | | (82) | |
| | | | | | | | | | | | | |
June 30, 2020 | 252.1 | | | 3 | | | 9,360 | | | 25,346 | | | (254) | | | — | | | 34,455 | |
Net income | — | | | — | | | — | | | 222 | | | — | | | — | | | 222 | |
Other comprehensive income | — | | | — | | | — | | | — | | | 142 | | | — | | | 142 | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
Repurchase and retirement of common stock | (2.9) | | | — | | | (106) | | | (652) | | | — | | | — | | | (758) | |
Dividends and dividend equivalents | — | | | — | | | — | | | (238) | | | — | | | — | | | (238) | |
Issuance of common stock under employee stock plans, net of related tax benefits | 0.2 | | | — | | | 98 | | | — | | | — | | | — | | | 98 | |
| | | | | | | | | | | | | |
September 30, 2020 | 249.4 | | | $ | 3 | | | $ | 9,352 | | | $ | 24,678 | | | $ | (112) | | | $ | — | | | $ | 33,921 | |
See accompanying notes.
Anthem, Inc.
Notes to Consolidated Financial Statements
(Unaudited)
September 30, 2021
(In Millions, Except Per Share Data or As Otherwise Stated Herein)
1. Organization
References to the terms “we,” “our,” “us” or “Anthem” used throughout these Notes to Consolidated Financial Statements refer to Anthem, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. References to the “states” include the District of Columbia and Puerto Rico, unless the context otherwise requires.
We are one of the largest health benefits companies in the United States in terms of medical membership, serving approximately 45 medical members through our affiliated health plans as of September 30, 2021. We offer a broad spectrum of network-based managed care plans to Individual, Group, Medicaid and Medicare markets. Our managed care plans include: Preferred Provider Organizations (“PPOs”); Health Maintenance Organizations (“HMOs”); Point-of-Service plans; traditional indemnity plans and other hybrid plans, including Consumer-Driven Health Plans; and hospital only and limited benefit products. In addition, we provide a broad array of managed care services to fee-based customers, including claims processing, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs and other administrative services. We provide an array of specialty and other insurance products and services such as pharmacy benefits management (“PBM”), dental, vision, life and disability insurance benefits, radiology benefit management and analytics-driven personal healthcare. We also provide services to the federal government in connection with our Federal Health Products & Services business, which administers the Federal Employees Health Benefits (“FEHB”) Program.
We are an independent licensee of the Blue Cross and Blue Shield Association (“BCBSA”), an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield (“BCBS”) licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross Blue Shield or Empire Blue Cross. We also conduct business through arrangements with other BCBS licensees as well as other strategic partners. Through our subsidiaries, we also serve customers in numerous states and Puerto Rico as AIM Specialty Health, Amerigroup, Aspire Health, Beacon, CareMore, Freedom Health, HealthLink, HealthSun, MMM, Optimum HealthCare, Simply Healthcare, and/or UniCare. Also, we provide PBM services through our IngenioRx, Inc. (“IngenioRx”) subsidiary. We are licensed to conduct insurance operations in all 50 states, the District of Columbia and Puerto Rico through our subsidiaries.
2. Basis of Presentation and Significant Accounting Policies
Basis of Presentation: The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for annual financial statements. We have omitted certain footnote disclosures that would substantially duplicate the disclosures in our 2020 Annual Report on Form 10-K, unless the information contained in those disclosures materially changed or is required by GAAP. Certain prior year amounts have been reclassified to conform to the current year presentation. In the opinion of management, all adjustments, including normal recurring adjustments, necessary for a fair statement of the consolidated financial statements as of and for the three and nine months ended September 30, 2021 and 2020 have been recorded. The results of operations for the three and nine months ended September 30, 2021 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2021, or any other period. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements as of and for the year ended December 31, 2020 included in our 2020 Annual Report on Form 10-K.
Certain of our subsidiaries operate outside of the United States and have functional currencies other than the U.S. dollar (“USD”). We translate the assets and liabilities of those subsidiaries to USD using the exchange rate in effect at the end of the period. We translate the revenues and expenses of those subsidiaries to USD using the average exchange rates in effect during the period. The net effect of these translation adjustments is included in “Foreign currency translation adjustments” in our consolidated statements of comprehensive income.
Cash and Cash Equivalents: We control a number of bank accounts that are used exclusively to hold customer funds for the administration of customer benefits, and we have cash and cash equivalents on deposit to meet certain regulatory requirements. These amounts totaled $186 and $170 at September 30, 2021 and December 31, 2020, respectively, and are included in the cash and cash equivalents line on our consolidated balance sheets.
Investments: We classify fixed maturity securities in our investment portfolio as “available-for-sale” and report those securities at fair value. Certain fixed maturity securities are available to support current operations and, accordingly, we classify such investments as current assets without regard to their contractual maturity. Investments used to satisfy contractual, regulatory or other requirements are classified as long-term, without regard to contractual maturity.
If a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it is more likely than not that we will have to sell the fixed maturity security before recovery of its amortized cost basis, we write down the fixed maturity security’s cost basis to fair value and record an impairment loss in our consolidated statements of income. For impaired fixed maturity securities that we do not intend to sell or if it is more likely than not that we will not have to sell such securities, but we expect that we will not fully recover the amortized cost basis, we recognize the credit component of the impairment as an allowance for credit loss in our consolidated balance sheets and record an impairment loss in our consolidated statements of income. The non-credit component of the impairment is recognized in accumulated other comprehensive (loss) income. Furthermore, unrealized losses entirely caused by non-credit-related factors related to fixed maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in accumulated other comprehensive (loss) income.
The credit component of an impairment is determined primarily by comparing the net present value of projected future cash flows with the amortized cost basis of the fixed maturity security. The net present value is calculated by discounting our best estimate of projected future cash flows at the effective interest rate implicit in the fixed maturity security at the date of purchase. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions regarding the underlying collateral, including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default rates, recoveries and changes in value. For all other securities, cash flow estimates are driven by assumptions regarding probability of default, including changes in credit ratings and estimates regarding timing and amount of recoveries associated with a default.
For asset-backed securities included in fixed maturity securities, we recognize income using an effective yield based on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the effective yield is recalculated to reflect actual payments to date and anticipated future payments. The net investment in the securities is adjusted to the amount that would have existed had the new effective yield been applied since the purchase date of the securities. Such adjustments are reported within net investment income.
The changes in fair value of our marketable equity securities are recognized in our results of operations within net realized gains and losses on financial instruments. Certain marketable equity securities are held to satisfy contractual obligations, and are reported under the caption “Other invested assets” in our consolidated balance sheets.
We have corporate-owned life insurance policies on certain participants in our deferred compensation plans and other members of management. The cash surrender value of the corporate-owned life insurance policies is reported under the caption “Other invested assets” in our consolidated balance sheets.
We use the equity method of accounting for investments in companies in which our ownership interest may enable us to influence the operating or financial decisions of the investee company. Our proportionate share of equity in net income of these unconsolidated affiliates is reported within net investment income. The equity method investments are reported under the caption “Other invested assets” in our consolidated balance sheets.
Investment income is recorded when earned. All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold.
We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in exchange for cash and securities collateral. We recognize the collateral as an asset, which is reported under the caption “Other current assets” in our consolidated balance sheets, and we record a corresponding liability for the obligation to return the collateral to the borrower, which is reported under the caption “Other current liabilities” in our consolidated balance sheets. The securities on loan are reported in the applicable investment category on our consolidated balance sheets. Unrealized gains or losses on securities lending collateral are included in accumulated other comprehensive (loss) income as a separate component of shareholders’ equity. The market value of loaned securities and that of the collateral pledged can fluctuate in non-synchronized fashions. To the extent the loaned securities’ value appreciates faster or depreciates slower than the value of the collateral pledged, we are exposed to the risk of the shortfall. As a primary mitigating mechanism, the loaned securities and collateral pledged are marked to market on a daily basis and the shortfall, if any, is collected accordingly. Secondarily, the collateral level is set at 102% of the value of the loaned securities, which provides a cushion before any shortfall arises. The investment of the cash collateral is subject to market risk, which is managed by limiting the investments to higher quality and shorter duration instruments.
Receivables: Receivables are reported net of amounts for expected credit losses. The allowance for doubtful accounts is based on historical collection trends, future forecasts and our judgment regarding the ability to collect specific accounts.
Premium receivables include the uncollected amounts from insured groups, individuals and government programs. Premium receivables are reported net of an allowance for doubtful accounts of $141 and $146 at September 30, 2021 and December 31, 2020, respectively.
Self-funded receivables include administrative fees, claims and other amounts due from self-funded customers. Self-funded receivables are reported net of an allowance for doubtful accounts of $49 and $54 at September 30, 2021 and December 31, 2020, respectively.
Other receivables include pharmacy rebates, provider advances, claims recoveries, reinsurance receivables, proceeds due from brokers on investment trades, accrued investment income, and other miscellaneous amounts due to us. These receivables are reported net of an allowance for doubtful accounts of $550 and $374 at September 30, 2021 and December 31, 2020, respectively.
Revenue Recognition: For our fee-based contracts, we had no material contract assets, contract liabilities or deferred contract costs recorded on our consolidated balance sheet at September 30, 2021. For the three and nine months ended September 30, 2021, revenue recognized from performance obligations related to prior periods, such as due to changes in transaction price, was not material. For contracts that have an original expected duration of greater than one year, revenue expected to be recognized in future periods related to unfulfilled contractual performance obligations and contracts with variable consideration related to undelivered performance obligations is not material.
Recently Adopted Accounting Guidance: In January 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2021-01, Reference Rate Reform (Topic 848) (“ASU 2021-01”). The amendments in ASU 2021-01 provide optional expedients and exceptions for applying GAAP to contract modifications and hedging relationships, subject to meeting certain criteria, that reference the London Interbank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued because of the reference rate reform. The provisions must be applied at a Topic, Subtopic, or Industry Subtopic level for all transactions other than derivatives, which may be applied at a hedging relationship level. We adopted ASU 2021-01 on January 7, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.
In October 2020, the FASB issued Accounting Standards Update No. 2020-08, Codification Improvements to Subtopic 310-20, Receivables—Nonrefundable Fees and Other Costs (“ASU 2020-08”). The amendments in ASU 2020-08 clarify when an entity should assess whether a callable debt security is within the scope of accounting guidance, which impacts the amortization period for nonrefundable fees and other costs. ASU 2020-08 became effective for interim and annual reporting periods beginning after December 15, 2020. The amendments are to be applied on a prospective basis as of the beginning of
the period of adoption for existing or newly purchased callable debt securities. We adopted ASU 2020-08 on January 1, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.
In December 2019, the FASB issued Accounting Standards Update No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). The amendments in ASU 2019-12 remove certain exceptions to the general principles in Accounting Standards Codification Topic 740. The amendments also clarify and amend existing guidance to improve consistent application. The amendments became effective for our annual reporting periods beginning after December 15, 2020. The transition method (retrospective, modified retrospective, or prospective basis) related to the amendments depends on the applicable guidance, and all amendments for which there is no transition guidance specified are to be applied on a prospective basis. We adopted ASU 2019-12 on January 1, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.
Recent Accounting Guidance Not Yet Adopted: In November 2020, the FASB issued Accounting Standards Update No. 2020-11, Financial Services—Insurance (Topic 944): Effective Date and Early Application (“ASU 2020-11”). The amendments in ASU 2020-11 make changes to the effective date and early application of Accounting Standards Update No. 2018-12, Financial Services—Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts (“ASU 2018-12”), which was issued in November 2018. The amendments in ASU 2020-11 have extended the original effective date by one year, and now the amendments are required for our interim and annual reporting periods beginning after December 15, 2022. The amendments in ASU 2018-12 make changes to a variety of areas to simplify or improve the existing recognition, measurement, presentation and disclosure requirements for long-duration contracts issued by an insurance entity. The amendments require insurers to annually review the assumptions they make about their policyholders and update the liabilities for future policy benefits if the assumptions change. The amendments also simplify the amortization of deferred contract acquisition costs and add new disclosure requirements about the assumptions insurers use to measure their liabilities and how they may affect future cash flows. The amendments related to the liability for future policy benefits for traditional and limited-payment co